Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
INmune Bio Inc. (NASDAQ:INMB) (the "Company" or "INmune Bio"), a clinical-stage inflammation and immunology com...
Scotiabank analyst George Farmer initiates coverage on INmune Bio (NASDAQ:INMB) with a Sector Outperform rating and announce...
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.63) by...
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and PathwaysBOCA RATON...
https://jitc.bmj.com/content/12/7/e008717
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage inflammation and immunology company, is set to join the...
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) ...
